SRI BHAVADHARANI,AKSHAYA VISWANATHAN,NEHA BRAHMA,VIMAL S,DR.MUTHULINGAM VIVEK
DOI: https://doi.org/The COVID-19 pandemic has significantly impacted individuals with chronic pulmonary diseases (CPDs), including chronic obstructive pulmonary disease (COPD), asthma, and pulmonary fibrosis. As the focus shifts from the acute phase of COVID-19 to its long-term respiratory consequencespost-COVID-19 survivors with pre-existing lung conditions face an elevated risk of disease progression of fibrosis, and persistent pulmonary complications. This review highlights recent innovative approaches that are reshaping the management of CPDs in the post-pandemic era. These include the use of artificial intelligence (AI) for personalized disease risk prediction, the development of targeted biological therapies, advances in stem cell-based regenerative medicine, cutting-edge imaging technologies for early detection, and the repurposing of antiviral and antifibrotic agents. Together, these innovations present new opportunities for improving the long-term respiratory health of individuals with CPDs, paving the way for more personalized and effective treatment strategies.
